- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update | 81 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| Di | Hemogenyx completes tech transfer for CAR-T therapy to CDMO | 4 | Investing.com | ||
| Di | Hemogenyx: Technologietransfer für CAR-T-Therapie erfolgreich abgeschlossen | 2 | Investing.com Deutsch | ||
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | Hemogenyx Pharma Plc - Tech Transfer Completion and Clinical Trial Update | 2 | RNS | ||
| 27.02. | Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights | 246 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the... ► Artikel lesen | |
| 27.02. | Hemogenyx Pharma Plc - Total Voting Rights | 3 | RNS | ||
| 23.02. | Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity | 234 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 23.02. | Hemogenyx Pharma Plc - Exercise of Warrants and Issue of Equity | 1 | RNS | ||
| 10.02. | Hemogenyx Pharmaceuticals PLC Announces Issue of Equity | 504 | ACCESS Newswire | The sentence "through a direct subscription for 313,333 new ordinary shares in the Company at a price of £7.50 per share" has been corrected to "through a direct subscription for 333,333 new ordinary... ► Artikel lesen | |
| 10.02. | Hemogenyx Pharma Plc - Issue of Equity - Correction | 2 | RNS | ||
| 10.02. | SMALL-CAP WINNERS & LOSERS: Hemogenyx raises funds for phase I trials | 4 | Alliance News | ||
| 10.02. | Hemogenyx Pharma Plc - Issue of Equity | 1 | RNS | ||
| 30.01. | Hemogenyx Pharma Plc - Total Voting Rights | - | RNS | ||
| 22.12.25 | Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares | 297 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update... ► Artikel lesen | |
| 22.12.25 | Hemogenyx Pharma Plc - Update on Admission of Shares | 1 | RNS | ||
| 18.12.25 | Hemogenyx Pharmaceuticals PLC - Issue of Equity | 329 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 18.12.25 | Hemogenyx Pharma Plc - Issue of Equity | 1 | RNS | ||
| 28.11.25 | Hemogenyx Pharma Plc - Total Voting Rights | - | RNS | ||
| 19.11.25 | Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus | 338 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION... ► Artikel lesen | |
| 19.11.25 | Hemogenyx shares to list on London Stock Exchange main market | 3 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 4,180 | +1,46 % | Innocan Pharma Corporation: Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest | The Debenture will be on the same terms as the Prior Debenture and will bear interest at the rate of 10% per annum and will mature at the earlier of: (i) 12 months from the date of issuance; and (ii)... ► Artikel lesen | |
| NOVERIS HEALTH SCIENCES | 1,170 | 0,00 % | BC Securities Commission: BCSC halts Noveris Health after incorrect FDA claim | ||
| CSPC PHARMA | 1,068 | -1,16 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME OF THE COMPANY | ||
| BACHEM | 72,70 | -0,07 % | Bachem FY25 Earnings Rise; Proposes Dividend Increase; Guides FY26 | WASHINGTON (dpa-AFX) - Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,520 | -1,81 % | SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 | ||
| BRIDGEBIO PHARMA | 63,28 | -0,19 % | BridgeBio Pharma, Inc.: Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 | - Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the... ► Artikel lesen | |
| OPUS GENETICS | 3,870 | -1,78 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of... ► Artikel lesen | |
| ONO PHARMACEUTICAL | 13,900 | +0,72 % | Dividendenbekanntmachungen (30.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,700 | +0,75 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results | Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 11,300 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| BAYER | 39,695 | -1,06 % | DAX-Check LIVE: Bayer, Rheinmetall, RTL Group, SMA Solar, SUSS im Fokus | Die wichtigsten deutschen Indizes haben die Handelswoche mit Verlusten beendet. Der DAX schloss bei 22.301 Punkten, ein Minus von 1,4 Prozent gegenüber dem Vortag. Trotz der erneuten Verlängerung des... ► Artikel lesen | |
| MERCK KGAA | 109,80 | -0,09 % | Merck-Aktie: Hohes Kurspotenzial! | Die Aktie der deutschen Merck KGaA steht nach ihrem Kursrücksetzer im vergangenen Monat wieder verstärkt im Fokus. Die Kombination aus breit aufgestelltem Geschäftsmodell, strukturellem Wachstum im... ► Artikel lesen | |
| GSK | 24,550 | +1,61 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem Kursziel von 1700 Pence belassen. Der Absatz des Myelofibrose-Mittels Ojjaara sei im bisherigen Quartal gegenüber... ► Artikel lesen | |
| NOVO NORDISK | 31,930 | -0,09 % | Novo Nordisk: Wichtige Zulassung - darum fällt die Aktie dennoch | In der Nacht zum Freitag hat der Biopharma-Konzern Novo Nordisk einen weiteren wichtigen Meilenstein errungen. Nach Verzögerungen konnte das Unternehmen die US-Zulassung für das Insulin-Präparat Awiqli... ► Artikel lesen | |
| PMGC | 5,700 | 0,00 % | PMGC Holdings Inc. Announces the Formation of New Subsidiary, NorthStrive Defense Tech to Target High-Growth Defense, Drone and Autonomous Systems Sector | NEWPORT BEACH, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC") (NASDAQ: ELAB), a diversified holding company, today announced the launch of a new wholly owned... ► Artikel lesen |
Das Unternehmen HEMOGENYX PHARMACEUTICALS PLC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-0,93 %) liegt der Kurs bei 10,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.